Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III ...

Omitting bolus 5-fluorouracil (5-FU) from combination chemotherapy for gastrointestinal (GI) cancers did not adversely affect survival and was associated with less toxicity, a review of a large ...

A new case report was published in Volume 12 of Oncoscience on December 23, 2025, titled "Silent toxicity: A rare case of 5-fluorouracil-induced hyperammonemic encephalopathy." In this report, Areti ...

From a historical perspective, 5-fluorouracil (5-FU) is widely recognized to have been one of the most useful and widely used antineoplastic drugs in cancer management, having previously been an ...

Adoption of neuroendocrine tumor (NET) research into treatment guidelines: Are rare cancers neglected? Background: Ampulla of vater cancer (AVC) is a rare malignancy. Limited data are available ...

Australian researchers have unlocked the mystery as to why the chemotherapy drug 5-Fluorouracil (5-FU) is not effective at treating certain cancers and have claimed a breakthrough in boosting its ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Using a bolus of Healon to form a barrier between the ...

A database search of PubMed and Embase was performed from 1965 to April 2012 using the terms 'actinic keratoses', 'solar keratoses', 'topical 5-fluorouracil', 'topical 5-FU', 'double-blind', ...

The My5‑FU assay (Saladax Biomedical Inc.), previously known as OnDose, is a CE‑marked in vitro diagnostic test designed to measure the levels of 5‑fluorouracil (5‑FU) chemotherapy in plasma samples.